Learning Objectives

By the end of this chapter, learners will be able to:
1. Identify indications and common contraindications to kidney transplantation.
2. Distinguish living from deceased donor transplantation and their implications.
3. Outline essential components of recipient and donor pre-transplant evaluation, including immunologic risk assessment.
4. Describe core surgical steps and immediate post-operative management priorities.
5. Recognize early and late immunological and non-immunological complications after transplantation.
6. Explain principles of induction and maintenance immunosuppression, major toxicities, and infection prophylaxis.
7. Plan long-term follow-up, including cardiovascular risk mitigation, cancer screening, vaccination, and adherence support.

24.1 Introduction to Kidney Transplantation

Kidney transplantation is the preferred renal replacement therapy for most patients with end-stage kidney disease (ESKD), offering better quality of life and, for many, improved survival compared with maintenance dialysis. Success reflects advances in donor-recipient matching, surgical technique, immunosuppression, and structured post-transplant care. Optimal outcomes require careful candidate selection, multidisciplinary coordination, and lifelong follow-up.

24.2 Indications and Contraindications

Indications

• Irreversible kidney failure approaching or requiring renal replacement therapy, irrespective of underlying etiology.
• Pre-emptive transplantation (before dialysis initiation) is often associated with superior outcomes when feasible.

Absolute contraindications (context- and center-dependent; require careful specialist review)

• Active, uncontrolled infection.
• Untreated or recently treated malignancy with a recurrence risk that precludes safe immunosuppression (waiting periods vary by cancer type and stage).
• Severe, non-reversible extrarenal comorbidity limiting post-transplant survival or rehabilitation (e.g., end-stage heart failure not amenable to therapy, decompensated cirrhosis without combined transplant candidacy).
• Ongoing substance use disorder without sustained recovery, or persistent inability to adhere to medical care despite support.
• Severe, uncontrolled psychiatric illness that impairs informed consent or adherence.

Relative contraindications (may be mitigated with evaluation and optimization)

• Advanced age with acceptable physiologic reserve.
• Obesity (consider weight management and surgical risk stratification).
• Significant atherosclerotic cardiovascular disease (address with guideline-directed evaluation/revascularization as appropriate).
• Chronic infections if virologically suppressed/treated (e.g., HIV, hepatitis B/C) with multidisciplinary input.
• High immunologic risk (sensitization, donor-specific antibodies) if desensitization or compatible allocation pathways are available.
• Risk of recurrent primary disease (e.g., FSGS, IgA nephropathy, atypical HUS) with individualized counseling and prevention strategies.

Notes:
– Age alone is not a contraindication.
– Eligibility criteria, cancer waiting periods, and infectious disease considerations vary by program and jurisdiction.

24.3 Donor Types

Deceased Donor Transplantation (DDT)

• Donors after brain death (DBD) or circulatory death (DCD).
• Advantages: No donor harm; broad availability through allocation systems.
• Considerations: Wait times; greater risk of delayed graft function (DGF), especially with DCD and prolonged cold ischemia; variable long-term outcomes influenced by donor age/comorbidity and ischemic times.

Living Donor Transplantation (LDT)

• Directed (related or unrelated), nondirected (altruistic), and paired/kidney exchange programs.
• Advantages: Shorter wait, elective scheduling, reduced cold ischemia, lower DGF rates, and generally superior graft survival.
• Considerations: Risks to a healthy donor (surgical complications, small long-term CKD/HTN risks), ethical safeguards (informed consent, voluntariness), and thorough medical/psychosocial evaluation.

24.4 Pre-transplant Evaluation

Both donor and recipient undergo comprehensive assessment to optimize safety and outcomes.

Recipient Evaluation

• Medical evaluation: Detailed history and exam; review of comorbidities (CVD, diabetes, infections, malignancy history).
• Cardiovascular assessment: ECG; echocardiography; noninvasive stress testing or angiography per risk profile and local protocols.
• Infectious disease screening: HIV, hepatitis B/C, CMV, EBV, syphilis, and latent TB (e.g., IGRA); dental evaluation; vaccination review and updates with inactivated vaccines.
• Malignancy screening: Age- and risk-appropriate cancer screening per local recommendations.
• Immunologic assessment:
• ABO typing and HLA typing.
• Panel reactive/cPRA and donor-specific antibodies (DSA); virtual and/or physical crossmatch.
• Risk stratification for rejection and consideration of desensitization or allocation strategies (e.g., paired exchange) if incompatible.
• Other: Imaging (e.g., vascular mapping if needed), frailty assessment, nutrition, bone/mineral review.
• Psychosocial: Adherence capacity, mental health, social supports, financial/logistical resources.

Living Donor Evaluation

• Medical: Kidney function (measured or well-validated eGFR confirmation), urinalysis and albuminuria, blood pressure profile, metabolic risk, nephrolithiasis history, pregnancy-related risk counseling when applicable.
• Imaging: Dedicated renal vascular anatomy (e.g., CT angiography); urologic evaluation.
• Psychosocial/ethical: Independent donor advocate, voluntariness/no coercion, comprehension of risks and alternatives.
• Surgical risk: Anesthetic clearance; selection of kidney for nephrectomy based on anatomy/function, preserving the donor’s better kidney.

24.5 Surgical Procedure and Immediate Post-operative Care

Procedure overview

• Allograft typically implanted extraperitoneally in the right or left iliac fossa.
• Vascular anastomoses: Donor renal vein to external iliac vein; donor renal artery to external or internal iliac artery (or common iliac).
• Ureteroneocystostomy (commonly Lich–Gregoir) with or without temporary ureteral stent.
• Key time intervals: Cold and warm ischemia times monitored; minimizing both reduces DGF risk.

Immediate post-operative care

• Hemodynamics/volume: Careful fluid and electrolyte management; monitor urine output and replace judiciously, avoiding fluid overload.
• Graft surveillance: Serial clinical assessment, serum creatinine, electrolytes, and point-of-care ultrasound/Doppler if perfusion concerns.
• Complication vigilance: Monitor for bleeding, vascular thrombosis, urinary leak/obstruction, lymphocele, hyperkalemia, and acid-base disturbances.
• Early immunosuppression: Initiate per protocol (induction agent followed by maintenance regimen).
• Infection prevention: Per local protocol—perioperative antibiotics; PJP (e.g., TMP-SMX), CMV prophylaxis/pre-emptive strategy based on donor/recipient serostatus; antifungal oral prophylaxis in some centers.
• Thromboprophylaxis, pain control, and early mobilization per surgical protocol; avoid nephrotoxins.

24.6 Complications of Kidney Transplantation

Immunological complications

• Hyperacute rejection: Minutes–hours due to preformed antibodies; now rare with contemporary crossmatching; graft loss if occurs.
• Acute rejection: Days–months (can present later). T cell–mediated and/or antibody-mediated. Diagnosis requires biopsy; treat with augmented immunosuppression (e.g., corticosteroids; lymphocyte-depleting therapy for steroid-resistant episodes; antibody-directed therapies for antibody-mediated rejection).
• Chronic active antibody-mediated rejection: Major cause of late graft dysfunction; manifests with progressive eGFR decline, proteinuria, donor-specific antibodies, and characteristic histology.

Non-immunological complications

• Early surgical: Hemorrhage, vascular thrombosis (arterial/venous), urinary leak/obstruction, lymphocele.
• Delayed graft function (DGF): Need for dialysis in the first week or failure of creatinine to fall; associated with DCD donors, prolonged ischemia, and recipient factors. Manage supportively, exclude obstruction/vascular issues, and consider biopsy to exclude rejection.
• Infections: Bacterial, viral (CMV, EBV, BK polyomavirus), and fungal/opportunistic infections. BK viremia/nephropathy typically managed by stepwise reduction of immunosuppression.
• Cardiovascular disease: Leading cause of death with a functioning graft; intensified risk factor management is essential.
• Malignancy: Increased risk of skin cancers (particularly SCC), PTLD (often EBV-associated), and others; emphasize sun protection and age-appropriate screening.
• Metabolic and drug-related:
• Calcineurin inhibitor (CNI) toxicity: Acute vasoconstriction and chronic nephrotoxicity; neurotoxicity, hypertension, hyperkalemia.
• mTOR inhibitor adverse effects: Dyslipidemia, mouth ulcers, proteinuria, edema, impaired wound healing, and increased lymphocele risk.
• Post-transplant diabetes mellitus (PTDM): Screen and manage per diabetes standards adapted to transplant.
• Bone/mineral disorders, anemia, electrolyte abnormalities (e.g., hypomagnesemia with CNIs).
• Recurrent or de novo kidney disease: FSGS, IgA nephropathy, complement-mediated TMA, among others; risk and prevention strategies vary by disease.

24.7 Immunosuppressive Therapy

Immunosuppression balances rejection prevention with infection, malignancy, and drug toxicity risks. Regimens are individualized based on immunologic risk, comorbidities, donor type, and center protocols.

• Induction therapy (perioperative):
• Interleukin-2 receptor antagonists (e.g., basiliximab) or lymphocyte-depleting agents (e.g., anti-thymocyte globulin, alemtuzumab) in higher-risk settings.
• Maintenance therapy (long-term, typically combinations):
• Calcineurin inhibitors (tacrolimus; cyclosporine as alternative).
• Antimetabolites (mycophenolate mofetil/mycophenolic acid; azathioprine as alternative).
• Corticosteroids (with center-specific minimization/withdrawal strategies in selected low-risk recipients).
• mTOR inhibitors (sirolimus/everolimus) as alternatives or adjuncts in selected scenarios (e.g., CNI minimization, certain malignancy risk profiles), accounting for wound healing and proteinuria considerations.

Key considerations:
– Therapeutic drug monitoring for CNIs and, in some centers, mTOR inhibitors; targets vary by time post-transplant, rejection risk, and assay.
– Significant drug and food interactions (e.g., azoles, macrolides, calcineurin inhibitor–level effects via CYP3A4/P-gp; grapefruit products).
– Infection prophylaxis tailored to risk:
– PJP: Typically for at least 6–12 months, sometimes longer.
– CMV: Prophylaxis or pre-emptive monitoring based on D/R serostatus (highest risk D+/R−).
– Consider antifungal prophylaxis per local epidemiology and regimen.
– Vaccination: Complete inactivated vaccines pre-transplant when possible; avoid live vaccines post-transplant.

24.8 Long-term Management

• Routine monitoring: Serum creatinine/eGFR, urinalysis/proteinuria, immunosuppressant troughs, BP, weight, glucose/HbA1c, lipids, electrolytes (including Mg and K), and markers of infection and allograft injury as per center protocols (e.g., donor-specific antibody surveillance in some programs).
• Cardiometabolic risk reduction: Optimize BP, lipids, and glycemic control; encourage exercise, weight management, and smoking cessation.
• Infection prevention: Ongoing prophylaxis/monitoring as indicated; prompt evaluation of febrile illness; up-to-date inactivated vaccinations (e.g., influenza, pneumococcal, hepatitis B, others per local guidance). Live vaccines are generally avoided post-transplant.
• Malignancy surveillance: Regular skin checks and sun protection; age-appropriate cancer screening; EBV monitoring in high-risk patients for PTLD.
• Medication adherence: Structured education, simplified regimens where possible, and multidisciplinary support; nonadherence is a major preventable risk for rejection and graft loss.
• Drug safety: Periodic review for interactions, nephrotoxins, and target levels; adjust for changing kidney function and comorbidities.
• Reproductive health: Contraception counseling; defer pregnancy planning until graft function is stable, immunosuppression is optimized, and risks have been reviewed with specialists.

SUMMARY

Key points
– Kidney transplantation is the treatment of choice for most patients with ESKD and is associated with superior quality of life and, for many, improved survival compared with dialysis.
– Living donor kidneys generally yield better short- and long-term outcomes with less DGF and shorter wait times.
– Thorough pre-transplant evaluation—including cardiovascular, infectious disease, malignancy, and immunologic risk assessment—is critical for safety and success.
– The kidney allograft is typically placed in the iliac fossa with vascular anastomoses to iliac vessels and ureteroneocystostomy to the bladder.
– Complications include immunologic rejection (acute and chronic), surgical issues, DGF, infections (CMV, BK), malignancies (skin cancer, PTLD), CVD, metabolic derangements, and drug toxicities.
– Immunosuppression uses induction plus maintenance (commonly CNI + antimetabolite ± steroids), tailored to risk and balanced against infection/malignancy.
– Long-term care emphasizes monitoring, infection prophylaxis, cardiovascular risk reduction, cancer screening, vaccination, and sustained adherence.

Quick guide
– Best overall option for suitable ESKD patients: consider pre-emptive transplantation where feasible.
– Living donation and paired exchange can expand access and improve outcomes.
– Rising creatinine post-transplant warrants prompt evaluation; biopsy is the diagnostic gold standard for rejection.
– Post-transplant care is lifelong and multidisciplinary; prevention (infections, CVD, skin cancer) is central to success.

CLINICAL PEARLS

Diagnostic
– Any early rise in creatinine after transplant is allograft dysfunction until proven otherwise: assess volume, exclude obstruction or vascular issues (ultrasound/Doppler), review drug levels, screen for infection, and consider biopsy.
– Allograft biopsy remains the gold standard for diagnosing and classifying rejection.
– Monitor for BK viremia in the first year; early detection enables immunosuppression reduction before nephropathy ensues.

Management
– Nonadherence to immunosuppressants is a leading preventable cause of late rejection and graft loss; invest in education and support.
– CNI nephrotoxicity can mimic rejection; correlate with drug levels, timing, and biopsy when in doubt.
– CMV prevention strategies depend on D/R serostatus; D+/R− recipients are highest risk and typically receive extended prophylaxis or intensive monitoring.
– mTOR inhibitors can impair wound healing and increase lymphocele risk; avoid initiation in the early post-operative period when surgical healing is ongoing.

Prognostic
– Living donor grafts have lower DGF risk and superior long-term survival compared with most deceased donor grafts.
– Pre-emptive transplantation and avoidance of DGF are associated with improved patient and graft outcomes.
– Cardiovascular events remain the leading cause of death with functioning grafts; aggressive risk factor control is essential.

VISUAL MATERIALS

Proposed figures and tables (to be created):
– Schematic: Transplant kidney placement in the iliac fossa with vascular and ureteral anastomoses.
– Flowchart: Approach to early allograft dysfunction (assess hydration, ultrasound/Doppler, labs/drug levels, biopsy).
– Table: Immunosuppressive agents by class, key adverse effects, and major drug interactions.
– Timeline: Infection risk and prophylaxis/monitoring across the first post-transplant year (e.g., bacterial, CMV, BK).
– Matrix: Donor/recipient CMV serostatus and recommended prevention strategy (prophylaxis vs pre-emptive).
– Checklist: Recipient and living donor evaluation essentials, including immunologic testing and psychosocial review.

MULTIPLE CHOICE QUESTIONS

1) Which therapy is generally preferred for suitable patients with end-stage kidney disease?
A) In-center hemodialysis
B) Peritoneal dialysis
C) Kidney transplantation
D) Conservative care without dialysis

Answer: C) Kidney transplantation
Explanation: Transplantation offers superior quality of life and, for many, better survival compared with dialysis modalities.

2) Which is an absolute contraindication to kidney transplantation in most programs?
A) Age >75 years with good functional status
B) Active, uncontrolled infection
C) Controlled HIV infection
D) Stable coronary disease after revascularization

Answer: B) Active, uncontrolled infection
Explanation: Immunosuppression would worsen uncontrolled infection; age and controlled comorbidities are not absolute barriers.

3) Which donor scenario is most strongly associated with delayed graft function?
A) Living donor
B) Deceased donor after brain death (DBD) with short cold ischemia time
C) Deceased donor after circulatory death (DCD) with prolonged cold ischemia
D) Living donor via paired exchange

Answer: C) Deceased donor after circulatory death (DCD) with prolonged cold ischemia
Explanation: DCD and prolonged ischemia increase DGF risk.

4) The transplanted kidney is most commonly placed:
A) Intraperitoneally in the left upper quadrant
B) Extraperitoneally in the iliac fossa
C) In the retroperitoneum replacing the native kidney
D) In the pelvis with arterial anastomosis to the aorta

Answer: B) Extraperitoneally in the iliac fossa
Explanation: Standard practice uses iliac vessels with ureteroneocystostomy.

5) Which immunosuppressive agent is a calcineurin inhibitor commonly associated with nephrotoxicity and neurotoxicity?
A) Mycophenolate mofetil
B) Tacrolimus
C) Azathioprine
D) Prednisone

Answer: B) Tacrolimus
Explanation: CNIs (tacrolimus > cyclosporine) can cause vasoconstrictive nephrotoxicity and neurotoxic effects.

6) A rising creatinine 3 months post-transplant with stable tacrolimus levels and no obstruction on ultrasound should be evaluated next by:
A) Starting empirical antibiotics
B) Kidney allograft biopsy
C) Increasing intravenous fluids for 48 hours
D) Ordering a CT angiogram

Answer: B) Kidney allograft biopsy
Explanation: Biopsy is the gold standard to diagnose and classify rejection and distinguish from other causes.

7) Which donor/recipient CMV serostatus confers the highest risk of CMV disease post-transplant?
A) D−/R−
B) D−/R+
C) D+/R−
D) D+/R+

Answer: C) D+/R−
Explanation: Seropositive donor and seronegative recipient carry the highest risk and typically require extended prophylaxis or intensive pre-emptive monitoring.

8) First-line management of BK viremia in a stable kidney transplant recipient is:
A) High-dose steroids
B) Increase mycophenolate dose
C) Reduce immunosuppression
D) Start broad-spectrum antibiotics

Answer: C) Reduce immunosuppression
Explanation: Stepwise reduction (often antimetabolite first) is the mainstay; there is no proven antiviral therapy.

9) Which of the following statements about vaccines in kidney transplant recipients is most accurate?
A) Live vaccines are routinely recommended post-transplant
B) Inactivated vaccines should be updated pre-transplant when possible
C) Vaccines are generally ineffective due to immunosuppression and should be avoided
D) Only influenza vaccination is recommended post-transplant

Answer: B) Inactivated vaccines should be updated pre-transplant when possible
Explanation: Inactivated vaccines are safe and recommended; live vaccines are generally avoided after transplant.

10) Which is the most important preventable factor contributing to late graft loss?
A) Recipient age
B) Nonadherence to immunosuppressive therapy
C) Deceased donor status
D) Female sex

Answer: B) Nonadherence to immunosuppressive therapy
Explanation: Nonadherence is a major preventable cause of rejection and late graft failure.

POWERPOINT PRESENTATION

Slide 1: Kidney Transplantation – Why and for Whom?
– Transplantation vs dialysis outcomes
– Indications and timing (including pre-emptive)
– Multidisciplinary nature of care

Slide 2: Donor Options and Allocation
– Living donor (directed, nondirected, paired exchange)
– Deceased donor (DBD, DCD)
– Impact on DGF and outcomes

Slide 3: Recipient Evaluation Essentials
– Cardiovascular, infectious disease, malignancy screening
– Immunologic work-up (ABO, HLA, DSA, crossmatch)
– Psychosocial and adherence assessment

Slide 4: Living Donor Assessment and Ethics
– Medical and imaging evaluation
– Donor risks and long-term considerations
– Informed consent and independent advocacy

Slide 5: Operative Overview and Early Care
– Iliac fossa implantation; vascular and ureteral anastomoses
– Cold/warm ischemia concepts
– Immediate post-op priorities and ultrasound/Doppler use

Slide 6: Immunosuppression Principles
– Induction options (IL-2RA vs depleting agents)
– Maintenance (CNI + antimetabolite ± steroids; mTOR in select cases)
– Drug monitoring and key interactions

Slide 7: Infection Prevention and Monitoring
– Perioperative antibiotics; PJP and CMV strategies
– BK screening and stepwise management
– Vaccination: inactivated preferred; avoid live vaccines post-transplant

Slide 8: Early and Late Complications
– Surgical issues and DGF approach
– Acute vs chronic rejection (biopsy-based)
– Metabolic toxicities, PTDM, malignancy risk

Slide 9: Long-term Care Roadmap
– Routine labs/levels; DSA in some centers
– CVD risk reduction and cancer screening
– Adherence strategies and patient education

Slide 10: Practical Pearls and Case Triggers
– Rising creatinine algorithm
– When to biopsy; when to adjust CNI
– Sun protection, drug interaction red flags

This educational content is original material created for NephroHub to support postgraduate clinical education.

Educational disclaimer: This chapter is for educational purposes only and is not a substitute for clinical judgment. Management should be individualized and aligned with local protocols, transplant program policies, and specialist consultation.

Visual learning: Kidney Transplantation

Presentation resource: The Kidney Hub clinical-series PowerPoint for Chapters 22–30 accompanies these chapters for teaching use.